All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Elsalys Biotech SAS, a 2013 spinout from Transgene SA, achieved a significant milestone with the finding that lead candidate inolimomab (Leukotac) showed clinical benefit during long-term follow-up of up to 8.5 years in individuals treated in the phase III study in acute steroid-resistant graft-vs.-host disease (SR-aGVHD). The positive overall survival (OS) outcome in the long-term analysis positions the Lyon, France-based company for a regulatory filing in the EU next year and puts discussions with commercial partners on the front burner – admirable achievements for a company of just 16 employees that's raised less than €20 million (US$22.8 million).